DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0183528A1 Maloney Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0183528A1 Maloney Et Al US 20100183528A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0183528A1 Maloney et al. (43) Pub. Date: Jul. 22, 2010 (54) ACNETREATMENT POWDER FOUNDATION Publication Classification (75)75) invenorInventors: Johnobtainstity. D. Malonev, Salisburv. NC (51) A61KInt. Cl. 8/368 (2006.01) Davidson NC (US) s A61O 1704 (2006.01) s A61O I/00 (2006.01) Correspondence Address: A6IP 7/10 (2006.01) INTELLECTUAL PROPERTY f TECHNOLOGY LAW (52) U.S. Cl. .......................................................... 424/60 PO BOX 14329 RESEARCH TRIANGLE PARK, NC 27709 (US) (57) ABSTRACT (73) Assignee: HARMONY LABORATORIES, Dry powder foundation formulations that include a sustained INC., Kannapolis, NC (US) release salicylic acid composition, an effective, buffering amount of one or more Salicylate ions, and one or more of Zinc (21) Appl. No.: 12/639,851 and titanium oxides, and pigments or colorants, are disclosed. 1-1. The formulations provide both acne treatment and preven (22) Filed: Dec. 16, 2009 tion, and Sunblock protection. The formulation can also O O include other Sunblocking or Sunscreen agents to prevent Related U.S. Application Data photoaging and Sunburn, such as avobenzone, and 3-ben (60) Provisional application No. 61/138.436, filed on Dec. Zophenone, and other cosmetically-acceptable active agents 17, 2008. and excipients. US 2010/0183528 A1 Jul. 22, 2010 ACNE TREATMENT POWDER FOUNDATION used as a foundation that provides both acne treatment and prevention and Sunblock protection. CROSS-REFERENCE TO RELATED 0007 Because the composition provides salicylic acid in APPLICATION the form of a Sustained-release composition, the salicylic acid remains effective for an extended period of time. Poly Pore 0001. This is a U.S. non-provisional of U.S. Provisional 450SA, a polymeric formulation including salicylic acid in an Patent Application No. 61/138.436 filed on Dec. 17, 2008. allyl methacrylate crosspolymer, is a representative poly The disclosure of the foregoing application is hereby incor meric Sustained-release form of Salicylic acid, though other porated herein by reference in its respective entirety, for all Sustained-release formulations can also be used. Further, as purposes, and the priority of Such application is hereby anti-acne additives, the formulation includes one or more claimed under the provisions of 35 USC 119. salicylates, ideally isolated as an extract from willow bark and/or aspen bark. In addition to the salicylic acid and one or BACKGROUND OF THE INVENTION more salicylates, the formulation can also include other anti 0002 Acne is the most common skin disorder in the US, acne agents, including Sulfur, benzoyl peroxide, and resorci and although this condition is generally associated with nol. puberty, it is not confined to adolescence and can persist well 0008. In addition to normal excipients found in dry pow into adulthood. The acne condition is a complex one, der foundations, the formulation includes Zinc oxide and/or impacted by a number of intrinsic and extrinsic factors, and, titanium dioxide as Sunblocking agents. The formulation can as such, must be treated with a multifaceted approach. Treat also include other Sunblocking or Sunscreen agents to prevent ment should address overproduction of sebum, hyperkerati photoaging and Sunburn, such as avobenzone, and 3-ben nization, overgrowth of P. acnes, and the ultimate blockage Zophenone. and irritation of the pilosebaceous follicle. Extrinsic factors, 0009. The foundation formulation typically also includes which exacerbate the acne condition, involve exfoliation via colorants/pigments, for example, inorganic colorants/pig harsh abrasives or mechanical Scrubbing, UV exposure, and ments, one example of which is a blend of iron oxide, bismuth Some topical and oral Substances. oxychloride, and mica. 0003 Salicylic acid is a relatively mild beta-hydroxy acid, 0010. In one embodiment, the composition further which is proven effective at correcting abnormal desquama includes one or more additional components, such as Zinc tion, the natural shedding of the outermost stratum corneum gluconate, Active Powder Purity LS9695, and pearl powder, cells. Its treatment benefits extend beyond that of the acne such as PPP-100 pearl powder. condition to include psoriasis, keratoses, and ichthyoses. By 0011. In one aspect of this embodiment, the formulation penetrating into the follicle, Salicylic acid encourages the has the following ingredients, in the ranges of weight percent sloughing of dead skin cells and other cellular debris and, ages provided below in Table 1. ultimately, clears blockages. Further benefits of its exfoliat ing action are improvements in skin texture and hyperpig TABLE 1 mentation. Representative Formulation Ranges 0004 While there are a wide variety of products on the market containing salicylic acid for treating the acne condi Ingredient Range % wiw tion, most are in the forms of lotions, creams, and liquids, Iron Oxide, Bismuth Oxychloride & Mica blend 40-75 including liquid foundation makeup. Incorporation of Sali Titanium Dioxide 5-40 cylic acid into color foundations is advantageous, as it helps Zinc Oxide 5-35 Poly-Pore 450SA O.10-12.OO to clear current breakouts while concealing them. Further Salicylic Acid & Allyl Methacrylates Crosspolymer more, continued use will help to prevent future breakouts. ABS White Willow Bark Extract Powder O.10-1O.OO Loose powder foundations are currently enjoying much Salix Nigra (Willow) Bark Extract popularity, as they impart a lightweight, natural feel on the Phytocide Aspen Bark Extract Powder O.10-1O.OO skin while providing great coverage, long wearability, oil Populus Tremuloides (Aspen) Bark Extract Givobio GZn O.10-1O.OO absorption, and diffuse the appearance of blemishes and other Zinc Gluconate skin imperfections. Providing a loose powder foundation Active Powder Purity LS9695 O.10-1O.OO with acne treatment benefits would represent an improvement Exfoliance Bamboo O.10-1O.OO over an already popular product type. Bambusa Arundinacea Stem Powder PPP-100 Pearl Powder O.10-1O.OO 0005. However, the presence of free salicylic acid may Pearl Powder serve to irritate the skin. Accordingly, it would be advanta geous to provide a loose powder foundation that provides the benefits of salicylic acid, while minimizing the degree of skin 0012. The foundation formulations combine the benefits irritation. The present invention provides such a foundation. of acne treatment and UV protection with lightweight cover age. The foundation formulations combat acne by reducing & SUMMARY OF THE INVENTION regulating sebum production, providing gentle exfoliation, destroying P acnes and other harmful microbes, soothing 0006. The present invention relates to a cosmetic compo irritation and inflammation, and restoring barrier function. sition, in the form of a dry powder foundation, that includes a The incorporation of Sunscreens also helps to improve acne, Sustained-release salicylic acid composition, an effective, as UV exposure is known to exacerbate the condition. buffering amount of one or more salicylate ions, and one or 0013. In some embodiments, the formulation can have a more of Zinc and titanium oxides. The composition can also sun protection factor (SPF) of 15 or more. The formulation include other cosmetically-acceptable actives and excipients can help heal blemishes and prevent future breakouts, clear found in dry powder foundations. The composition can be blockages, and help improve skin texture and hyperpigmen US 2010/0183528 A1 Jul. 22, 2010 tation remaining after breakouts. The Salicylic acid/salicylate well as non-active agents (excipients) can be present. The combination reduces and absorbs surface sebum, provides various active agents and optional components are described gentle exfoliation and stimulates natural exfoliation, and pro in more detail below. vides anti-microbial activity. The formulation can provide 0022 Acne Treatment antioxidant activity, soothe skin and mitigate irritation, pro 0023 The anti-acne additives include a combination of a vides a modern, natural look, provide excellent coverage and Sustained-release salicyclic acid composition, and salicy wearability, and diffuse the look of blemishes and uneven lates, either in the form of a natural extract or as a pure pigmentation compound. Examples of extracts that include Salicylates 0014. The present invention will be better understood with include willow bark and aspen bark. The amount of the sus reference to the following detailed description. tained-release salicylic acid composition, by weight percent, typically ranges from between about 0.10 to about 12.00, DETAILED DESCRIPTION which provides between about 0.05 to about 6.00 free sali cylic acid. The amount of the Salicylates, by weight percent, 0015. A dry powder foundation formulation is disclosed. typically ranges from between about 0.10 to about 10.00, The dry powder foundation formulation includes conven which can be present in the form of an extract of a natural tional foundation ingredients, as well as Sunblocking agents product that includes salicylates, such as willow bark and and anti-acne additives. The formulation provides controlled aspen bark. When in the form of an extract, the extract itself release of salicylic acid, and includes extracts containing one is typically present in a range of between about 0.055 to about or more salicylate salts. 5.50 free salicylic acid. 0024 Salicylic acid is a mild keratolytic agent, which DEFINITIONS promotes
Load more

Recommended publications
  • Novel Derivatives of Bio-Affecting Phenolic Compounds and Pharmaceutical Composition Containing Them
    Europaisches Patentamt European Patent Office © Publication number: 0046 270 A1 Office europeen des brevets ™ EUROPEAN PATENT APPLICATION @ Application number: 81106277.7 © Int. CI.3: C 07 C 103/78, C 07 C 93/26, C 07 C 69/24, C 07 C 1 53/07, @ Date of filing: 12.08.81 C07C 69/28 // C07C1 25/065 <§) Priority: 13.08.80 US 177825 © Applicant: INTERx RESEARCH CORPORATION, 2201 West 21 st Street, Lawrence Kansas 66044 (US) © I nventor : Bodor, Nicholas S., 31 5 Southwest 91 st Street, ® Dateofpublicationofapplication:24.02.82 S^^S^mHariMBM Bulletin m/b Terrace, Gainesville, Florida 32605 (US) Inventor: Pogany, Stefano A., 520 Louisiana Street, Lawrence Kansas 66044 (US) @ Designated Contracting States : AT BE CH DE FR GB IT ® Representative: Abitz, Walter, Dr.-lng. et al, Abitz, Mori, LI LU NL SE Gritschneder P.O. Box 86 01 09, D-8000 Munchen 86 (DE) Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them. Novel@ Novel transient prodrug forms of bio-affecting phe- amyl, CH2ONO2,CH2ON02, -CH2OCOR2 or any non-heterocyclic nolic compounds are selected from the group consisting of member of the group defined by R2Rz above; and n.isn is at least those having the structural formula (I): one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol o etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): R2-C-X-CH-0- (I) I O R, II R2-C-X-CH-0- -RM-i-O-C-R2 (II) wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl;alky!;
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • China Japan United States Europe
    Inhibitor United States China Toll Free: +1 877 796-6397 Toll Free: 400-668-6834 Fax: +1 832 582-8590 Fax: 021-68591981 E-mail: [email protected] E-mail: [email protected] Europe Japan Tel: +49-89-46148500 Tel: + 81 3-5632-9610 Fax: +49-89-461485022 Fax: + 81 3-5632-9619 E-mail: [email protected] E-mail: [email protected] Protein Tyrosine Kinase PI3K/Akt/mTOR MAPK Inhibitors Cytoskeletal Signaling Selleck Chemicals supplies over 3,000 Apoptosis + inhibitors used in the study of cell 3000 Epigenetics Cell Cycle Inhibitors signaling pathways. Ubiquitin Signaling DNA Damage Stem Others Cells Neuronal Signaling Product Citations Selleck products have been cited in more than 12000 studies from various SCI journals. (Cell, Nature, Science: 61 studies) Compound Libraries Bioactive Compound Library 2659 compounds Nature. 2017, 541(7638):481-487. Nature. 2015, 521(7552):357-61. Science. 2016, 354(6315). Nature. 2017, 10.1038/nature21064. Nature. 2015, 521(7552):316-21. Science. 2016, 353(6302):929-32. Kinase Inhibitor Library Nature. 2016, 540(7631):119-123. Nature. 2015, 520(7549):683-7. Science. 2016, 352(6283):353-8. 430 inhibitors Nature. 2016, 539(7629):437-442. Nature. 2015, 520(7547):368-72. Science. 2016, 352(6282):189-96. Nature. 2016, 539(7628):304-308. Nature. 2015, 519(7543):370-3. Science. 2016, 351(6277):aad3680. FDA-approved Drug Library 1443 compounds Nature. 2016, 539(7627):54-58. Nature. 2015, 518(7538):254-7. Science. 2013, 341(6146):651-4. Nature. 2016, 538(7626):477-482. Nature. 2015, 517(7536):583-8.
    [Show full text]
  • Design Cosmetic Ingredients El Camp De Bossa - Les Tallades - La Figuerassa - El Pouet De Tomàs
    biogründl gründl bio biogründl factory Polígono Les Fallulles, nave 34 - sector 2 - 08620 Sant Vicenç dels Horts. Barcelona (SPAIN) Tel. +34 93 660 55 12 - Fax +34 93 660 55 13 - www.biogrundl.es biogründl station design cosmetic ingredients El Camp de Bossa - Les Tallades - La Figuerassa - El Pouet de Tomàs. Tarragona (SPAIN) biogründl factory Polígono Les Fallulles, nave 34 - sector 2 Sant Vicenç dels Horts Barcelona (SPAIN) biogründl station El Camp de Bossa, Les Tallades, La Figuerassa, El Pouet de Tomàs Tarragona (SPAIN) biogründl, s.l., a company located in Barcelona, whose activity is l+D+i and production in the field of active and auxiliary substances which are completely new for cosmetic industry. biogründl, s.l. was founded in 2002 being supported by a great human team with large technical and commercial experience. biogründl, s.l. is filling the gap in the area of cosmetic and dermatologic active substances, which was mainly the field for great sized companies engaged in the commercialization of many products involved in several fields of the chemical industry. Opposite to this concept, biogründl, s.l. has to do exclusively with substances destined to Cosmetology and Dermatology. biogründl, s.l. has acquired in 2012 ten Ha of land, biogründl station, in Tarragona (Spain), which is used to ecological plantation to obtain their own vegetable actives. This way, biogründl, s.l. ensures the origin and the obtaining of such actives. Its market strategy is based on the following concepts: • Contribution of new concepts in formulations to satisfy the proactive demands of Cosmetics. • Fast and dynamic response to customers’ need with the corresponding personal assistance.
    [Show full text]
  • EQUILIBRIUM-10 LINE the Authentic Expression of Balance in Your Skin
    01 EQUILIBRIUM-10 LINE The authentic expression of balance in your skin EQUILIBRIUM-10 LINE FIRST STEP TO BEAUTY Its effectiveness is immediate in the recovery of your skin’s optimum pH, and the balance of dry or oily skin. 01. Oxygenating The activity of cells receiving oxygen triples and cell division increased by 20%. 02. Restructuring increases cell activity, encouraging the elasticity of youthful skin. 03. Hydrating A balancing effect on the mantle, smoothing and closing pores. EQUILIBRIUM-10 LINE ACTIVE INGREDIENTS AQUAXTREM TM Placebo 25 AQUAXTREM™ 20 • Activates the own mechanisms of the skin for a long-lasting moisturization. + 11,6 % + 9,6 % • Skin hydration from the inside. 15 • Stratum corneum resistance and cohesion. • Improvement of barrier function and NMF. 10 • Complementary activity: anti-aging. % increase in hydration % increase in hydration 5 0 D29 D31 Increase of AQUAXTREM™ and placebo as compared to control WRINKLES CITRUSTEM™ Product T0 T56 % Decrease Placebo 3,58 3,47 3,17* • Organizes and redensifies dermis structure. CITRUSTEM™ (3%) 3,54 3,19 9,89* • Repairs extracelular matrix. CITRUSTEM™ (placebo) 3,54 3,19 6,7* • Result: Firmer skin. * Statistically significant (Wilcoxon, p<0.05) • Recovers the elasticity of 12 years ago. EQUILIBRIUM-10 LINE 01 BALANCING DERMO-PROTECTIVE FLUID ACTION It contains sweet almond oil and eucalyptus, which give it soothing, softening and anti-inflammatory properties. It cleanses and balances skins of all types, eliminating impurities and respecting the integrity of the epicutaneous mantle that protects the skin. HOW TO USE Apply the product with circular movements to clean the face and neck.
    [Show full text]
  • Fragances Extracts
    PERSONAL CARE extracts petroleum jellies and paraffins active ingredients antioxidants hair conditioners oils amino acids colourants emollients preservatives fragances vitamins emulsifiers fatty alcohols sunscreens multifunctionals waxes pearl shine concentrates moisturisers opacifiers At Escuder, we are specialists in distributing raw materials aimed primarily at the cosmetics, pharmaceutical, veterinary, food and dietary industries. Since 1896, our aim has been to provide the highest quality in our services and products. Escuder is a dynamic company, with a highly specialised team and all the necessary resources to constantly update our processes and incorporate new tools which enable us to establish close connections with our customers and suppliers. Our extensive experience, sound industry knowledge, reliability and professionalism allow us to adapt to our customers’ needs, providing the highest levels of quality and safety in managing the products and services we offer. This is our catalogue of products aimed primarily at the cosmetics industry. Here you will find a wide range of materials which we hope will be of interest to you and meet your needs. Actives 4-7 Amino Acids 7 Antibacterials, Antifungals 8 Antioxidants 8 Emollients 8-9 Emulsifiers / Fatty Alcohols 10-11 Exfoliants 11 Extracts 12 Fragrances 12 Hair Conditioners 13 Humectants 14 Oils 14-15 Pearl Shine Concentrates / Opacifiers 15 Ph Regulators 15 Preservatives 16 Rheological Modifiers 17 Sequestrant Agents 17 Solubilizers 17 Sunscreen Filters 18 Surfactants 18-19 Sweeteners
    [Show full text]
  • High-Value Oxy-Pharmaceuticals from P450 BM3 ‘Gatekeeper’ Mutations
    High-value oxy-pharmaceuticals from P450 BM3 ‘gatekeeper’ mutations A thesis submitted to The University of Manchester for the degree of Doctor of Philosophy in the Faculty of Science and Engineering 2018 Laura N. Jeffreys School of Chemistry BLANK PAGE 2 Table of Contents Figures……. ………………………………………………………………………………..8 Tables……………………………………………………………………………………...10 Supplementary Figures………………………………………………………………….. 11 List of Abbreviations…………………………………………………………………….. 13 Abstract…………………………………………………………………………………... 15 Acknowledgements ………………………………………………………………………16 Declaration……………………………………………………………………………….. 17 Copyright Statement…………………………………………………………………….. 18 Preface to the Journal Format Thesis………………………………………………….. 19 Author contributions……………………………………………………………………. 21 Chapter 1: General Introduction……………………………………………………... 23 1.1. An Overview of Cytochromes P450……………………………………... 23 1.1.1. The Evolution and Nomenclature of Cytochromes P450…………….23 1.1.2. The History of Cytochrome P450 Research ………………………….28 1.1.3. The P450 Catalytic Cycle …………………………………………….32 1.1.4. The Structure of P450 Enzymes ……………………………………...38 1.1.5. Unusual P450 Proteins ……………………………………………….43 1.2. The Natural Fusion Protein P450 BM3 (CYP102A1) ……………………47 1.2.1. The Structure of P450 BM3 ………………………………………….48 1.2.2. Electron Transfer Within P450 BM3 ………………………………...54 1.2.3. P450 BM3 Mutagenesis and the Gatekeeper Mutants ……………….58 1.3. Real-World Applications of P450 Enzymes ……………………………...61 1.3.1. Using P450 BM3 in the Pharmaceutical Industry ……………………63 1.3.2. Using other P450
    [Show full text]
  • Sensibilisation Aux Drogues Chimiothérapeutiques Des Tumeurs P53 Négatives Par Activation De La Phosphatase Wip1 Victor Clausse
    Sensibilisation aux drogues chimiothérapeutiques des tumeurs P53 négatives par activation de la phosphatase Wip1 Victor Clausse To cite this version: Victor Clausse. Sensibilisation aux drogues chimiothérapeutiques des tumeurs P53 négatives par activation de la phosphatase Wip1. Sciences agricoles. Université Bourgogne Franche-Comté, 2017. Français. NNT : 2017UBFCI002. tel-02094528 HAL Id: tel-02094528 https://tel.archives-ouvertes.fr/tel-02094528 Submitted on 9 Apr 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE DE BOURGOGNE FRANCHE-COMTE UFR Sciences de la Vie, Terre et Environnement Ecole doctorale Environnements - Santé THÈSE Présentée pour l’obtention du titre de DOCTEUR DE L’UNIVERSITE DE BOURGOGNE FRANCHE-COMTE Discipline : Biochimie et Biologie Moléculaire SENSIBILISATION AUX DROGUES CHIMIOTHERAPEUTIQUES DES TUMEURS P53-NEGATIVES PAR ACTIVATION DE LA PHOSPHATASE WIP1 Présentée et soutenue par Victor CLAUSSE Le 22 Mars 2017 Membres du jury : Pr Marc Bardou .........................................................................
    [Show full text]